Pepleomycin, Interferon and Estracyt in the Treatment of Poorly Differentiated Prostatic Carcinoma
An investigation using Pepleomycin in the treatment of prostatic carcinoma was reported at the WHO centre meeting on prostatic carcinoma in March 1979 in Stockholm (1). Some degree of objective and subjective improvement was observed in a series of six patients with stage C and D tumors. Side effects including gastro-intestinal disturbances, fever and dermatological symptoms were noted.
KeywordsPain Relief Acid Phosphatase Prostatic Carcinoma Fine Needle Aspiration Biopsy Subjective Improvement
Unable to display preview. Download preview PDF.
- 1.T. Niijima and K. Koiso, Effect of Pepleomycin in Prostatic Carcinoma. A Preliminary Report. Scand. J. Urol. Nephrol.Suppl. 177 (1980).Google Scholar